Atlas Trials

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Clinical trial NCT04752696 · COMPLETED

Trial details

NCT number
NCT04752696
Sponsor
Cardiff Oncology
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Ductal Adenocarcinoma
Start date
2021-05-25
Primary completion
2024-12-24
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.